Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering

Bausch Health (NYSE:BHC) and its dermatology unit Ortho Dermatologics launched Biafine® Skin Recovery Emulsion for U.S. consumers via select online channels on April 14, 2026.

Rhea-AI Summary

Bausch Health (NYSE:BHC) and its dermatology unit Ortho Dermatologics launched Biafine® Skin Recovery Emulsion for U.S. consumers via select online channels on April 14, 2026. First developed in France in 1971, Biafine is a lightweight, clinically supported emulsion for dry, sensitive, or stressed skin.

The product is available directly to patients through select online retailers including Amazon, and dermatology practices can supply it via the Ortho Dermatologics Direct platform when recommended by a clinician.

Argus Apr 14 session

-0.70% close to close Open Argus

Details

News Market Reaction – BHC

On Apr 14, the day this news came out, BHC closed 0.70% below the previous close.

Data tracked by StockTitan Argus for the Apr 14 session.

Key Figures

Initial formulation year: 1971

Initial formulation year

1971

Biafine first developed in France

Historical Context

5 past events · Latest: Mar 31

5 events

1. Mar 31

   Earnings date notice

   24h Move

   +7.4%

   Set date and call details for Q1 2026 financial results release.

2. Mar 26

   Scholarship program

   24h Move

   +0.8%

   Announced 2026 ASPIRE HIGHER scholarships for students with dermatologic conditions.

3. Feb 23

   Aesthetic device launch

   24h Move

   -2.5%

   Launched Clear + Brilliant Touch laser in Canada after Health Canada approval.

4. Feb 19

   Product milestone

   24h Move

   -4.2%

   Marked 25 years of ARESTIN with note of expanded commercial presence.

5. Feb 18

   Earnings results

   24h Move

   -4.2%

   Reported Q4 and full-year 2025 revenue and EBITDA growth with 2026 guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

emulsion, dermatology, dermatologists

3 terms

emulsion medical

"Biafine® is a lightweight emulsion formula designed to support the skin's"

An emulsion is a stable mixture of two liquids that normally don't mix, such as oil and water, where tiny droplets of one are dispersed throughout the other—think of shaking salad dressing so the oil breaks into fine droplets in the vinegar. For investors, emulsions matter because they are a common way drugs, vaccines, cosmetics and foods are formulated; the type and stability of an emulsion affect product effectiveness, manufacturing complexity, shelf life, regulatory approval and potential market value.

dermatology medical

"We are proud to offer dermatology practices and patients access to a formula"

Dermatology is the medical specialty focused on the diagnosis and treatment of conditions affecting the skin, hair and nails, including rashes, infections, chronic diseases and cosmetic concerns. It matters to investors because breakthroughs, approved treatments, new devices or shifts in care demand can change revenue prospects for drugmakers, device makers and clinics—think of it like weather changes that reshape a farmer’s crop yields, where regulatory approvals and patient demand drive financial outcomes.

dermatologists medical

"recognized by dermatologists and consumers for its unique texture and"

Medical specialists who diagnose and treat conditions of the skin, hair and nails, performing exams, minor procedures and prescribing therapies. Investors care because dermatologists act like the frontline gatekeepers for new drugs, devices and procedures in skin health — their adoption, prescribing patterns and clinical trial involvement strongly influence sales, market acceptance and regulatory outcomes for related companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The skin recovery emulsion for dry, sensitive, or stressed skin is now available through select online channels

LAVAL, QC, April 14, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced Biafine^® Skin Recovery Emulsion is now offered through convenient online ordering in the United States. The well-known French skincare formula is available through select online channels.

First developed in France in 1971, Biafine^® is a lightweight emulsion formula designed to support the skin's natural barrier function while helping to maintain skin hydration and comfort. For decades, the formula has been recognized by dermatologists and consumers for its unique texture and versatility in skincare routines. The renowned formulation is gentle enough for sensitive skin, helps soothe skin, and is clinically proven to support the skin barrier. Its versatility in skincare routines has contributed to Biafine's recognition among dermatologists and consumers alike.

Tom Stern, Vice President and General Manager of the Ortho Dermatologics business reflected, "We are proud to offer dermatology practices and patients access to a formula that has earned the trust of both professionals and consumers for decades."

Biafine is available directly to patients through select online channels, including Amazon. Dermatology practices can provide the product through the Ortho Dermatologics Direct platform which supports in-office access when a dermatologist recommends it as part of a skincare regimen.

For more information about Biafine, please visit www.biafine.com. 

About Biafine^®
Biafine^® is a French-developed skincare emulsion introduced in 1971, designed to support the skin's natural barrier function while maintaining hydration and comfort. For decades, the formula has been recognized by dermatologists and consumers for its unique texture and versatility in skincare routines. Biafine is offered in the United States as a cosmetic for skincare.

About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our dermatology business, Ortho Dermatologics is one of the largest prescription and aesthetic dermatology businesses dedicated to helping patients in the treatment of a range of conditions, including psoriasis, onychomycosis, actinic keratosis, acne, atopic dermatitis and other dermatoses. More information can be found at https://www.ortho-dermatologics.com and connect with us on LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.

Biafine is a registered trademark of Ortho Dermatologics or its affiliates. © 2026 Ortho Dermatologics or its affiliates.
Investor Contact:	Media Contact:
Garen Sarafian	Katie Savastano
ir@bauschhealth.com	corporate.communications@bauschhealth.com
877-281-6642 (toll-free)	(908) 569-3692
BHC-PRODUCT

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-healths-dermatology-business-ortho-dermatologics-announces-the-launch-of-biafine-an-iconic-french-skincare-product-through-convenient-online-ordering-302739556.html

SOURCE Bausch Health Companies Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When did Bausch Health (BHC) launch Biafine online in the U.S.?

Biafine launched online in the U.S. on April 14, 2026, via select retailers. According to the company, the product is available through select online channels, including Amazon, and through Ortho Dermatologics Direct for dermatology practices.

What is Biafine Skin Recovery Emulsion and what skin types is it for (BHC)?

Biafine is a lightweight emulsion formulated for dry, sensitive, or stressed skin. According to the company, it supports the skin barrier, helps maintain hydration, and is clinically proven to soothe and be gentle for sensitive skin.

How can dermatology practices obtain Biafine from Ortho Dermatologics (BHC)?

Dermatology practices can obtain Biafine through the Ortho Dermatologics Direct platform for in-office access. According to the company, the platform supports clinicians recommending the product as part of a skincare regimen.

Will patients be able to buy Biafine on Amazon and other online stores (BHC)?

Yes, patients can buy Biafine through select online channels including Amazon. According to the company, the product is being offered via convenient online ordering to increase patient access in the United States.

What clinical benefits does Biafine offer according to Ortho Dermatologics (BHC)?

Biafine is described as clinically proven to support the skin barrier and soothe skin while maintaining hydration. According to the company, its long-established French formula is recognized for gentle tolerance and versatility in skincare routines.